Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Table 1 Patients’ characteristics at diagnosis (n = 1102) and first hepatocellular carcinoma recorded treatment n (%)

	All patients (n = 1102)
Age - Median (Q1-Q3), yr	68 (60-74)
Gender
Male/Female	943 (86)/159 (14)
Liver disease
Alcoholism/HCV/HBV/MS/ Other	452 (41)/297 (27)/66 (6)/99 (9)/188 (17)
Cirrhosis	895 (81)
Child - Pugh grade
A/B	653 (73)/242 (27)
Tumor Size (Q1-Q3) mm	43 (20-75)
Multifocal	654 (59)
Nodules
< 3/≥ 3	633 (57)/469 (43)
Portal vein thrombosis	452 (41)
Infiltrative HCC	469 (43)
AFP - Median [Q1-Q3], ng/mL	53 (7-1300)
ECOG (PS)
0/1-2/3-4	553 (50)/506 (46)/43 (4)
BCLC stage
A/B/C/D	187 (17)/177 (16)/658 (60)/80 (7)
Treatment allocation
Resection/RFA ± TACE	259 (23.5)
TACE	260 (23.5)
Sorafenib	342 (31)
Other palliative treatments	56 (5)
Supportive care	185 (17)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; MS: Metabolic syndrome; AFP: Alpha-foetoprotein; ECOG PS: Eastern Cooperative Oncology Group Performance Status; BCLC: Barcelona Clinic Liver Cancer; RFA: Radiofrequency ablation; TACE: Trans arterial chemoembolization.